{"nctId":"NCT01134107","briefTitle":"Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use","startDateStruct":{"date":"2010-11"},"conditions":["Diabetes Mellitus, Type 1"],"count":133,"armGroups":[{"label":"Insulin Lispro 6 Day (6D)","type":"EXPERIMENTAL","interventionNames":["Drug: Insulin Lispro 6 Day (6D)"]},{"label":"Insulin Aspart 6 Day (6D)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin Aspart 6 Day (6D)"]}],"interventions":[{"name":"Insulin Lispro 6 Day (6D)","otherNames":["Insulin Lispro Formulation","Humalog","LY275585"]},{"name":"Insulin Aspart 6 Day (6D)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with type 1 diabetes (World Health Organization criteria) for at least 24 months\n* Treated with continuous subcutaneous insulin infusion (CSII) therapy for the previous 6 months\n* Mean total daily insulin dose for 3 days prior to screening less than or equal to 46 units/day if using a 300-Unit reservoir, less than or equal to 30 units/day if using a 200 unit reservoir, or less than or equal to 26 units/day if using a 180 unit reservoir\n* Baseline body mass index (BMI) less than or equal to 35.0 kilograms per meter squared (kg/m2)\n* Baseline glycated hemoglobin A1c (HbA1c) 5% to 9%\n\nExclusion Criteria:\n\n* Impaired renal function (serum creatinine greater than or equal to 2.0 milligrams per deciliter (mg/dL))\n* Legal blindness\n* Have had any episode in the 12 months prior to screening of hypoglycemic coma, seizures, or disorientation\n* Have had hypoglycemia unawareness (routinely asymptomatic at blood glucose less than 45 mg/dL \\[2.5 millimoles per liter (mmol/L)\\]) in the 12 months prior to screening.\n* Have had any emergency room visits or hospitalizations due to poor glucose control in the 12 months prior to screening.\n* Have had a pump-related infusion site abscess in the 12 months prior to screening.\n* Have had multiple, clinically significant occlusions as judged by the investigator.\n* Have had any infection with Staphylococcus aureus in the past 5 years\n* Have one of the following concomitant diseases: presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease, or any other serious disease considered by the investigator to be exclusionary.\n* Participants with malignancy other than basal cell or squamous cell skin cancer who have not yet been treated, are currently being treated, or who were diagnosed less than 5 years ago.\n* Have had a blood transfusion or severe blood loss within the 3 months prior to screening or have known hemoglobinopathy, hemolytic or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with HbA1c methodology.\n* Are receiving chronic systemic glucocorticoid therapy, or have received such therapy within the 4 weeks preceding screening.\n* Have an irregular sleep/wake cycle in the investigator's opinion.\n* Have a known hypersensitivity or allergy to any of the study insulins or their excipients\n* Are breastfeeding or pregnant, or intend to become pregnant during the course of the study, or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable.\n* Are currently enrolled in, or discontinued within the last 30 days from a clinical trial involving off-label use of an investigational drug or device, or currently enrolled in any other type of medical research not to be scientifically or medically compatible with this study.\n* Are unwilling or unable to comply with the use of a data collection device to directly record data from the participant.","healthyVolunteers":false,"sex":"ALL","minimumAge":"13 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean of Last Six 7-point Self Monitored Blood Glucose (SMBG) Taken on Day 6 for Insulin Lispro 6D and Insulin Aspart 6D Pump Reservoir In-use","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.83","spread":"1.55"},{"groupId":"OG001","value":"8.43","spread":"1.97"}]}]}]},{"type":"SECONDARY","title":"Mean SMBG","description":"Mean SMBG for combined periods; all reported SMBG values on Days 1-6, Day 2, and Day 6 for Insulin Lispro 6D and Insulin Aspart 6D.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.70","spread":"2.51"},{"groupId":"OG001","value":"8.47","spread":"2.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.56","spread":"2.51"},{"groupId":"OG001","value":"8.40","spread":"2.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.93","spread":"2.68"},{"groupId":"OG001","value":"8.57","spread":"2.64"}]}]}]},{"type":"SECONDARY","title":"Mean Daily Insulin Dose (Total, Basal, and Bolus)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.90","spread":"8.43"},{"groupId":"OG001","value":"32.48","spread":"8.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.83","spread":"5.26"},{"groupId":"OG001","value":"17.71","spread":"5.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.26","spread":"6.21"},{"groupId":"OG001","value":"16.09","spread":"6.23"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to 12 Weeks for Each Treatment in Glycated Hemoglobin A1c (HbA1c) Values","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.54"},{"groupId":"OG001","value":"-0.31","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieve or Maintain a Glycated Hemoglobin A1c (HbA1c) Less Than or Equal to 6.5% and Less Than 7%","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline to 12 Weeks for Daily Insulin Dose (Total, Basal, and Bolus)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.21","spread":"8.94"},{"groupId":"OG001","value":"4.97","spread":"7.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"3.51"},{"groupId":"OG001","value":"1.91","spread":"3.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.19","spread":"5.58"},{"groupId":"OG001","value":"1.80","spread":"4.70"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Having a Hyperglycemic Episode","description":"A hyperglycemic episode was defined as an event with (1) a measured blood glucose concentration \\>250 milligrams per deciliter (mg/dL) (13.9 millimoles per liter \\[mmol/L\\]) and ≥3 hours after eating, or (2) a measured blood glucose concentration \\>300 mg/dL (16.7 mmol/L) and \\<3 hours after eating","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6","spread":null},{"groupId":"OG001","value":"98.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hyperglycemic Episode Rate Per 30 Days","description":"Hyperglycemia was defined as an episode with (1) a measured blood glucose concentration \\>250 milligrams per deciliter \\[mg/dL\\] (13.9 millimoles per liter \\[mmol/L\\]) and ≥3 hours after eating, or (2) a measured blood glucose concentration \\>300 mg/dL (16.7 mmol/L) and \\<3 hours after eating. Rate is presented as the number of hyperglycemic episodes adjusted for 30 days.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.47","spread":"9.25"},{"groupId":"OG001","value":"14.23","spread":"10.19"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Pump Complications","description":"Overall pump complications are defined as any combination of the following, reported by the participant: tubing clogged, tubing kinked, tubing disconnect, tubing pulled out, blood in tubing, too much heat, too much cold, empty reservoir, low battery, occlusion alarm, no delivery alarm, skin abscess at site, excessive redness at site, swelling (not nodule) at site, bleeding at site, bruising at site, reservoir change (infusion set change reason only), and other. When either a reservoir change or an infusion set change was reported, participants were questioned whether the change occurred early (prior to 6 days). If he/she responded 'yes', then the reported change was recorded as a premature change.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.5","spread":null},{"groupId":"OG001","value":"44.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":null},{"groupId":"OG001","value":"70.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Pump Complications Rate Per 30 Days","description":"Overall pump complications are defined as any combination of the following reported by the participant: tubing clogged, tubing kinked, tubing disconnect, tubing pulled out, blood in tubing, too much heat, too much cold, empty reservoir, low battery, occlusion alarm, no delivery alarm, skin abscess at site, excessive redness at site, swelling (not nodule) at site, bleeding at site, bruising at site, reservoir change (infusion set change reason only), and other. When either a reservoir change or an infusion set change was reported, participants were questioned whether the change occurred early (prior to 6 days). If he/she responded 'yes', then the reported change was recorded as a premature change.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"0.93"},{"groupId":"OG001","value":"0.45","spread":"1.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"1.41"},{"groupId":"OG001","value":"1.10","spread":"1.47"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Having a Hypoglycemic Episode","description":"A Documented Hypoglycemic Episode is defined as an event which is associated with a documented blood glucose (BG) concentration of \\<= 70 mg/dL (3.9 mmol/L).\n\nAll Reported Hypoglycemic Episodes are defined as an event which is associated with\n\n1. reported signs and symptoms of hypoglycemia, and/or\n2. a documented blood glucose (BG) concentration of \\<= 70 mg/dL (3.9 mmol/L)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null},{"groupId":"OG001","value":"93.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"99.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hypoglycemic Episode Rate Per 30 Days","description":"All Reported Hypoglycemic Episodes are defined as an event which is associated with\n\n1. reported signs and symptoms of hypoglycemia, and/or\n2. a documented blood glucose (BG) concentration of \\<= 70 mg/dL (3.9 mmol/L)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.94","spread":"10.69"},{"groupId":"OG001","value":"18.90","spread":"11.58"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline to 12 Week Endpoint for Each Treatment in Weight","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"2.25"},{"groupId":"OG001","value":"0.56","spread":"2.15"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline to 12 Weeks Endpoint for Each Treatment in Blood Pressure","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.25","spread":"14.71"},{"groupId":"OG001","value":"-1.36","spread":"12.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.61","spread":"10.36"},{"groupId":"OG001","value":"-1.57","spread":"9.13"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":127},"commonTop":["Nasopharyngitis","Influenza","Gastroenteritis","Toothache","Bronchitis"]}}}